Home > Publications Database > Predicting longitudinal basal forebrain volume in mild cognitive impairment: the role of sex and APOE4 genotype > print

001     283061
005     20251230103619.0
024 7 _ |a 10.1002/alz70856_100257
|2 doi
024 7 _ |a pmid:41444919
|2 pmid
024 7 _ |a pmc:PMC12738425
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-01468
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Grazia, Alice
|0 P:(DE-2719)9001307
|b 0
|u dzne
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Predicting longitudinal basal forebrain volume in mild cognitive impairment: the role of sex and APOE4 genotype
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767015791_31205
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Imaging studies showed early atrophy of the cholinergic basal forebrain already at prodromal stages of sporadic Alzheimer's disease. It is well known that women and carriers of the APOE4 allele are more likely to develop the disease, however, the mechanisms underlying the role of APOE4 in the pathogenesis of the disease as a whole and at the sex-specific level are still unknown. In this study we aim at exploring the impact of sex and APOE genotype on longitudinal measures of basal forebrain volume in mild cognitive impairment (MCI) compared to cognitively normal (CN) individuals.We analyzed MRI scans of individuals from the DELCODE study (mean age: 71 years), comprising 936 CN and 536 MCI at baseline, and 490 CN and 306 MCI at follow-up (average time:10.88 months). We performed longitudinal volume segmentation and conducted a linear mixed-effect model to calculate the effect of APOE genotype, sex, diagnosis, time and their interactions over normalized basal forebrain volume.Sex was a significant predictor of basal forebrain volume (β = -0.016, t = -3.32, p = 0.001)), with male sex and MCI diagnosis (β = -0.018, t = -6.75, p < 0.0001) being significantly associated with lower volume. However, neither APOE status (β = -0.008, t = -1.39, p = 0.165) nor time (β = -0.00002, t = -0.18, p = 0.858) had significant effects, nor did the interactions between sex, APOE status and time (Figure).Results showed that basal forebrain volume was significantly smaller in males and individuals with MCI, but the rate of change over time did not appear to differ significantly between these groups, ApoE status, or based on sex.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Apolipoproteins E
|2 NLM Chemicals
650 _ 7 |a Apolipoprotein E4
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: pathology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Apolipoproteins E: genetics
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a Basal Forebrain: pathology
|2 MeSH
650 _ 2 |a Basal Forebrain: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Sex Factors
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Atrophy
|2 MeSH
700 1 _ |a Levin, Fedor
|0 P:(DE-2719)2814217
|b 1
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 2
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 3
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 4
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 5
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 6
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 7
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 8
|u dzne
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 9
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 10
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 11
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 12
|u dzne
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 13
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 14
|e Last author
|u dzne
773 _ _ |a 10.1002/alz70856_100257
|g Vol. 21 Suppl 2, no. Suppl 2, p. e100257
|0 PERI:(DE-600)2201940-6
|n Suppl 2
|p e100257
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283061/files/DZNE-2025-1468.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283061/files/DZNE-2025-1468.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283061
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9001307
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2814217
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 1
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 2
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 3
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 4
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 5
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 6
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 7
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 8
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 9
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 10
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 11
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21